



(51) International Patent Classification:

A61K 39/215 (2006.01) A61P 11/00 (2006.01)
A61K 39/12 (2006.01) A61P 31/14 (2006.01)

(21) International Application Number:

PCT/US2023/066330

(22) International Filing Date:

28 April 2023 (28.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/336,499 29 April 2022 (29.04.2022) US
63/348,451 02 June 2022 (02.06.2022) US

(71) Applicants: **XANADU BIO, INC.** [US/US]; 980 Idlewild Road, Gladwyne, PA 19035 (US). **YALE UNIVERSITY** [US/US]; 2 Whitney Avenue, New Haven, CT 06511 (US).

(72) Inventors: **IWASAKI, Akiko**; 980 Idlewild Road, Gladwyne, PA 19035 (US). **SALTZMAN, W., Mark**; 980 Idlewild Road, Gladwyne, PA 19035 (US). **GOLMAN-ISRAELOW, Benjamin**; 980 Idlewild Road, Gladwyne, PA 19035 (US). **MAO, Tianyang**; 980 Idlewild Road, Gladwyne, PA 19035 (US). **TURNER, Bruce**; 980 Idlewild Road, Gladwyne, PA 19035 (US). **WIDER, Todd**; 980 Idlewild Road, Gladwyne, PA 19035 (US).

C/o Xanadu Bio, Inc., 980 Idlewild Road, Gladwyne, PA 19035 (US).

(74) Agent: **CHAI, Deping** et al.; Morgan Lewis & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHOD FOR ENHANCING IMMUNITY




FIG. 18

(57) Abstract: The invention relates to a method of enhancing immunity, mRNA-based vaccines for SARS-CoV-2 have demonstrated the enormous potential of mRNA therapeutics for safe and effective use in the general population. However, more recent studies have demonstrated decreasing vaccine effectiveness in terms of asymptomatic infection as well as symptomatic and severe infections starting around 4 months post second dose with mRNA-lipid nanoparticles (LNP) based regimens.

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

07 December 2023 (07.12.2023)